- Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
- DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
- Castle Biosciences Reports First Quarter 2024 Results
- Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
- Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
- Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
- Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
- Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
- Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Castle Biosciences Announces Updates to its Board of Directors
More ▼
Key statistics
On Thursday, Castle Biosciences Inc (CSTL:NMQ) closed at 24.42, -8.54% below its 52-week high of 26.70, set on May 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.38 |
---|---|
High | 25.23 |
Low | 23.22 |
Bid | 18.50 |
Offer | 25.17 |
Previous close | 23.54 |
Average volume | 341.89k |
---|---|
Shares outstanding | 27.61m |
Free float | 26.77m |
P/E (TTM) | -- |
Market cap | 649.87m USD |
EPS (TTM) | -1.15 USD |
Data delayed at least 15 minutes, as of May 09 2024 21:00 BST.
More ▼